BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ning L, Lin W, Hu X, Fan R, Liang X, Wu Y, Shen S, Yu R, Sun J, Hou J. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat 2017;24:1043-51. [PMID: 28581186 DOI: 10.1111/jvh.12733] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Fabrizi F, Cerutti R, Ridruejo E. Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert Rev Clin Pharmacol 2019;12:867-74. [PMID: 31456441 DOI: 10.1080/17512433.2019.1657828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Reference Citation Analysis]
3 Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [DOI: 10.1111/jvh.13313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Su Q, Liu Y, Li J. Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e12089. [PMID: 30142868 DOI: 10.1097/MD.0000000000012089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Mak LY, Liu SH, Yap DY, Seto WK, Wong DK, Fung J, Chan TM, Lai CL, Yuen MF. In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. Dig Dis Sci 2019;64:3630-41. [PMID: 31280390 DOI: 10.1007/s10620-019-05717-0] [Reference Citation Analysis]
6 Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine HHTW, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatol Int 2021. [PMID: 34822056 DOI: 10.1007/s12072-021-10271-x] [Reference Citation Analysis]
7 Li DY, Yin WJ, Yi YH, Zhang BK, Zhao J, Zhu CN, Ma RR, Zhou LY, Xie YL, Wang JL, Zuo SR, Liu K, Hu C, Zhou G, Zuo XC. Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population. Kidney Int 2019;95:636-46. [PMID: 30709663 DOI: 10.1016/j.kint.2018.10.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
8 Gu J, Yu G, Zhang X, Zhang S, Cai H, Ye C, Yang Y, Li D, Tong Z, Shen H, Chen H, Ding F, Lai X, Liu J, Xu M, Wu W. Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China. Virol J 2021;18:19. [PMID: 33441170 DOI: 10.1186/s12985-021-01491-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]